Evidence map›Paper›PMID 41795804›Full record

ArticleCancer medicine2026

SLC12A8 Drives Immune Evasion and Metastasis in Luminal B Breast Cancer by Inducing CD8

Zhiyong Liu, Ran Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhiyong LiuBreast Treatment Center, the First Affiliated Hospital of Gannan Medical University, Ganzhou, China.ORCID https://orcid.org/0000-0003-3277-7626
Ran ChenBreast Treatment Center, the First Affiliated Hospital of Gannan Medical University, Ganzhou, China.

Funding

Gannan Medical University
6 · The paper itself

Abstract

backgroundTo investigate the role and mechanism of SLC12A8 in the progression of Luminal B breast cancer.

methodsData from TCGA, GTEx, and HPA databases were used to analyze SLC12A8 expression and its prognostic value in breast cancer. qPCR was performed to validate SLC12A8 expression in various breast cancer cell lines. The correlation between SLC12A8 and immune cell infiltration was analyzed using ImmuCellAI and TIMER databases. Gene set enrichment analysis (GSEA) was employed to predict signaling pathways associated with SLC12A8. In vitro, siRNA-mediated knockdown of SLC12A8 or treatment with the TLR pathway inhibitor GIT27 was used to assess the effects on the TLR pathway, CD8

resultsSLC12A8 was significantly upregulated in breast cancer tissues and cell lines, and its high expression correlated with poor patient prognosis. Bioinformatic analysis and experimental validation confirmed that high SLC12A8 expression was strongly associated with reduced infiltration and functional inhibition of CD8

conclusionSLC12A8 promotes immune evasion and metastasis in Luminal B breast cancer by inducing CD8

Indexed as

Breast NeoplasmsCD8-Positive T-LymphocytesSolute Carrier Family 12Toll-Like ReceptorsTumor EscapeCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansNeoplasm MetastasisPrognosisSignal TransductionT-Cell ExhaustionTumor MicroenvironmentSolute Carrier Family 12Toll-Like ReceptorsCD8+ T‐cell exhaustionImmune evasionLuminal B breast cancerSLC12A8Toll‐like receptor signaling pathway

Identifiers

PMID41795804
PMCPMC12967574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.